BioLife Solutions (BLFS) Misses Q3 EPS by 7c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BLFS Hot Sheet
Price: $38.61 --0%
EPS Growth %: +400.0%
Financial Fact:
Net Loss: -969K
Today's EPS Names:
COHR, ATS, SICP, More
EPS Growth %: +400.0%
Financial Fact:
Net Loss: -969K
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
BioLife Solutions (NASDAQ: BLFS) reported Q3 EPS of ($0.23), $0.07 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $40.7 million versus the consensus estimate of $42.02 million.
GUIDANCE:
BioLife Solutions sees FY2022 revenue of $160-164 million, versus the consensus of $163.4 million.
For earnings history and earnings-related data on BioLife Solutions (BLFS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- MagnaChip (MX) Misses Q3 EPS by 9c
- Suncor Energy (SU) Tops Q3 EPS by 172c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
